RxDoctor Payments Data

Rachel Vann, NP

Family · Oak Ridge, TNNPI 1801248349

Payments from drug & device makers

$11,151in general payments, 2019–2025

Across 437 payments — averaging $25.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Bayer$967
  • Sumitomo Pharma America, Inc.$722
  • Dendreon Pharmaceuticals LLC$713
  • Pfizer$662
  • Astellas Pharma US Inc$618
  • plus $6K from 40 others

What the payments were for

  • Food & beverage$11,06199%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,151 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$647,480
Medicare patients
792
Services billed
20,059

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide21$364,428
XtandiEnzalutamide19$234,036
GemtesaVibegron179$104,824
MyrbetriqMirabegron118$70,861
OrgovyxRelugolix27$68,007
Methenamine Hippurate109$7,263
Solifenacin Succinate139$6,602
Trimethoprim66$4,572
Testosterone13$4,109
Tamsulosin Hcl306$3,177
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst74$2,742
Fosfomycin Tromethamine12$2,543
Estradiol32$2,398
Finasteride155$2,228
Testosterone Cypionate33$2,118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$1,795$364,42821 claims
Astellas Pharma US IncXtandi, Myrbetriq$618$304,898137 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$722$172,831206 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Oak Ridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →